These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39412913)

  • 21. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
    Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
    Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N; Yen PL; Schwarz MA; Schwarz RE
    J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
    Daylami R; Muilenburg DJ; Virudachalam S; Bold RJ
    J Exp Clin Cancer Res; 2014 Dec; 33(1):102. PubMed ID: 25499121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells.
    Patki M; Saraswat A; Bhutkar S; Dukhande V; Patel K
    Exp Cell Res; 2021 Aug; 405(2):112660. PubMed ID: 34048785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma.
    Hii LW; Lim SE; Leong CO; Chin SY; Tan NP; Lai KS; Mai CW
    BMC Complement Altern Med; 2019 Sep; 19(1):257. PubMed ID: 31521140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
    Kim R; Yamauchi T; Husain K; Sebti S; Malafa M
    Anticancer Res; 2015 Sep; 35(9):4599-604. PubMed ID: 26254348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
    Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
    Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
    Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
    Jung DB; Yun M; Kim EO; Kim J; Kim B; Jung JH; Wang E; Mukhopadhyay D; Hammond E; Dredge K; Shridhar V; Kim SH
    Oncotarget; 2015 Mar; 6(7):4992-5004. PubMed ID: 25669977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine.
    Xu H; Li Y; Paxton JW; Wu Z
    Pharm Res; 2021 Jul; 38(7):1209-1219. PubMed ID: 34189639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
    Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
    Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma.
    Sugimoto T; Iwagami Y; Kobayashi S; Yamanaka C; Sasaki K; Yamada D; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Ann Surg Oncol; 2024 Jun; 31(6):3718-3736. PubMed ID: 38502294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
    Gitto SB; Pandey V; Oyer JL; Copik AJ; Hogan FC; Phanstiel O; Altomare DA
    Mol Pharm; 2018 Feb; 15(2):369-376. PubMed ID: 29299930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
    Bader Y; Hartmann J; Horvath Z; Saiko P; Grusch M; Madlener S; Maier S; Oehler L; Fritzer-Szekeres M; Heller N; Alken RG; Krupitza G; Szekeres T
    Cancer Lett; 2008 Feb; 259(2):231-9. PubMed ID: 18023527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.